Navigation Links
SPO Announces Completion of Rebranding Program

SPO Announces Completion of Rebranding Program -- NEW YORK, November 4, 2010 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Web Site, Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, General Sports, New Products & Services Click to view news release full screen  

SPO Announces Completion of Rebranding Program


NEW YORK, November 4, 2010 /PRNewswire-FirstCall/ --

- Company Positioned for Growth via Consumer-Related Wellness Applications

SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced it has completed its rebranding program so it can operate primarily on consumer-related wellness applications. The company will now focus on several vertical applications based on its proprietary technology platform. Moving forward, SPO will operate divisionally through the SPO Wellness(TM), SPO Medical, SPO Baby and SPO Security product lines. Additionally, a new corporate web site and company logo has been launched that can be viewed at

Michael Braunold, President and Chief Executive Officer of SPO commented, "This is an important milestone for the company and its shareholders. With our ability to now focus on vertical market opportunities, we can maximize the value of our technology through commercial partnerships to promote our consumer product lines. Our experience in developing and launching several successful medical product offerings enables us to now effectively focus on mass-market, consumer opportunities going forward. Our primary market is in the wellness space and we are in the latter stages of preparing for launch of our new SPO Wellness(TM) product line. We achieved this through our partnership with Brewer Sports International (BSI), the world's fastest growing multi-faceted advisory firms with a focus on the business of sports and wellness."

As part of this launch program, SPO recently announced that it has signed with several high-profile, professional athletes who have agreed to endorse the SPO Wellness(TM) line of products. This includes the world's first performance monitoring wristband, known as the Wellness 10k(TM). The Wellness 10k(TM) is designed for both children and adults and features a display function to continuously measure the number of daily activities against preset recommended goals. Furthermore, an innovative heart-rate monitor sports watch has also been developed to measure continuous heart-rate without the need to wear a conventional chest strap, unlike many other heart-rate monitor watches that are on the market.

Both SPO Wellness(TM) products are currently at an advanced stage of development and SPO expects the Wellness 10k(TM) wristband to be launched later this month for test marketing followed by a full commercial roll-out in 2011. Braunold continued, "We believe our partnership with BSI along with the secured endorsements and our rebranding efforts will help us bring a cost-effective solution to the vast consumer wellness market, which in turn contributes to potentially increasing value for the SPO shareholders."

About SPO

SPO (SPOM) is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-enhancing information within four key markets: medical care; sports and wellness; homecare monitoring and security. Its patented technology uses information gathered from the reflectance of light on the human body, in a noninvasive manner, to monitor key vital signs. The company manufactures its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. For more information, visit

Forward Looking Statements

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, market acceptance of our products and new product applications, timing of new product launches, success of the Company's rebranding program, product performance, size of prospective markets, revenues assessments, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of competing products, changes in our operating strategy or development plans patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2009. We undertake no obligation to revise or update any forward-looking statement for any reason.


Twitter: Facebook: Contacts regarding this release: Michael Braunold, Chief Executive Officer +1-866-991-7766

SOURCE SPO Medical Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):